^
    19h
    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study (clinicaltrials.gov)
    P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220) • Hemady (dexamethasone tablets)
    7d
    Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=0, Withdrawn, Roswell Park Cancer Institute | N=21 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carfilzomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Hemady (dexamethasone tablets) • selvigaltin (GB1211)
    8d
    MonumenTAL-3: A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment (clinicaltrials.gov)
    P3, N=864, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Jun 2029 --> May 2028 | Trial primary completion date: Feb 2026 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • dexamethasone injection
    8d
    MajesTEC-7: A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=1590, Recruiting, Janssen Research & Development, LLC | N=568 --> 1590
    Enrollment change
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    9d
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2027 --> Oct 2026
    Trial completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    14d
    IFM2017_03: Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (clinicaltrials.gov)
    P3, N=294, Active, not recruiting, University Hospital, Lille | Trial completion date: Oct 2027 --> Oct 2026
    Trial completion date
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    16d
    A Phase 1 Study Of Venetoclax, Dexamethasone, Bortezomib, And Daratumumab (VDBD) For Adolescent And Young Adult Patients With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And Lymphomas (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    Venclexta (venetoclax) • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    19d
    EXCALIBER: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=939, Active, not recruiting, Celgene | Trial primary completion date: Mar 2026 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • iberdomide (CC-220)
    1m
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P1, N=258, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    lenalidomide • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    A Study of Daratumumab (clinicaltrials.gov)
    P3, N=500, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2026 --> Jan 2029
    Trial primary completion date
    |
    lenalidomide • Darzalex (daratumumab) • carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1m
    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure (clinicaltrials.gov)
    P1, N=30, Recruiting, Augusta University | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    Daratumumab in STK11 Mutated NSCLC (clinicaltrials.gov)
    P2, N=8, Completed, NYU Langone Health | Recruiting --> Completed | N=14 --> 8 | Trial completion date: Dec 2026 --> Nov 2025 | Trial primary completion date: May 2026 --> Nov 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    STK11 (Serine/threonine kinase 11)
    |
    STK11 mutation
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)